Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases

Journal of the Neurological Sciences

Volumn 207, Issue 1-2, 2003, Pages 71-76

  Lorenzl, S ^a   Albers, D S ^a   LeWitt, P A ^b   Chirichigno, J W ^a   Hilgenberg, S L ^c   Cudkowicz, M E ^c   Beal, M F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cerebrospinal fluid; MMP 2; MMP 9; Neurodegeneration; TIMP 1; TIMP 2

Indexed keywords

GELATINASE A; GELATINASE B; PROTEIN PRECURSOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CEREBROSPINAL FLUID ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DEGENERATIVE DISEASE; GEL; HUMAN; HUNTINGTON CHOREA; MEASUREMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; ZYMOGRAPHY;

EID: 12244291232     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00398-2     Document Type: Conference Paper

References (34)

1. Albers D.S., Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative. J. Neural Transm., Suppl. 59:2000;133-154.
2. Backstrom J.R., Lim G.P., Cullen M.J., Tokes Z.A. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J. Neurosci. 16:1996;7910-7919.
3. Harkness K.A., Adamson P., Sussman J.D., Davies-Jones G.A., Greenwood J., Woodroffe M.N. Dexamethasone regulation of matrix metalloproteinase expression. Brain. 123:2000;698-709.
4. Oh L.Y., Larsen P.H., Krekoski C.A., Edards D.R., Donovan F., Werb Z.et al. Matrix metalloproteinase-9 gelatinase B is required for process outgrowth by oligodendrocytes. J. Neurosci. 19:1999;8464-8475.
5. Gottschall P.E., Deb S. Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons. Neuroimmunomodulation. 3:1996;69-75.
6. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 21:1998;75-80.
7. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta. 1477:2000;267-283.
8. Kolb S.A., Lahrtz F., Paul R., Leppert D., Nadal D., Pfister H.W.et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J. Neuroimmunol. 84:1998;143-150.
9. Paul R., Lorenzl S., Koedel U., Sporer B., Vogel U., Frosch M.et al. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis. Ann. Neurol. 44:1998;592-600.
10. Clark A.W., Krekoski C.A., Bou S.S., Chapman K.R., Edwards D.R. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci. Lett. 238:1997;53-56.
11. Leppert D., Ford J., Stabler G., Grygar C., Lienert C., Huber S.et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain. 121:1998;2327-2334.
12. Asahina M., Yoshiyama Y., Hattori T. Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain. Clin. Neuropathol. 20:2001;60-63.
13. Peress N., Perillo E., Zucker S. Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain. J. Neuropathol. Exp. Neurol. 54:1995;16-22.
14. Lim G.P., Backstrom J.R., Cullen M.J., Miller C.A., Atkinson R.D., Tokes Z.A. Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J. Neurochem. 67:1996;251-259.
15. Beuche W., Yushchenko M., Mader M., Maliszewska M., Felgenhauer K., Weber F. Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. NeuroReport. 11:2000;3419-3422.
16. Yushchenko M., Weber F., Mader M., Scholl U., Maliszewska M., Tumani H.et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J. Neuroimmunol. 110:2000;244-251.
17. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 17:1967;427-442.
18. Brooks B.R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "clinical limits of amyotrophic lateral sclerosis" workshop contributors. J. Neurol. Sci. 124:1994;96-107. [Supplement].
19. Kleiner D.E., Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 218:1994;325-329.
20. Friedberg M.H., Glantz M.J., Klempner M.S., Cole B.F., Perides G. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer. 82:1998;923-930.
21. Perides G., Charness M.E., Tanner L.M., Peter O., Satz N., Steere A.C.et al. Matrix metalloproteinases in the cerebrospinal fluid of patients with Lyme neuroborreliosis. J. Infect. Dis. 177:1998;401-408.
22. Opdenakker G., Van den Steen P.E., Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22:2001;571-579.
23. Backstrom J.R., Miller C.A., Tokes Z.A. Characterization of neutral proteinases from Alzheimer-affected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J. Neurochem. 58:1992;983-992.
24. Moutsiakis D., Mancuso P., Krutzsch H., Stetler-Stevenson W., Zucker S. Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect. Tissue Res. 28:1992;213-230.
25. Rivera S., Tremblay E., Timsit S., Canals O., Ben-Ari Y., Khrestchatisky M. Tissue inhibitor of metalloproteinases-1 (TIMP-1) is differentially induced in neurons and astrocytes after seizures: evidence for developmental, immediate early gene, and lesion response. J. Neurosci. 17:1997;4223-4235.
26. Jaworski D.M. Differential regulation of tissue inhibitor of metalloproteinase mRNA expression in response to intracranial injury. Glia. 30:2000;199-208.
27. La Fleur M., Underwood J.L., Rappolee D.A., Werb Z. Basement membrane and repair of injury to peripheral nerve: defining a potential role for macrophages, matrix metalloproteinases, and tissue inhibitor of metalloproteinases-1. J. Exp. Med. 184:1996;2311-2326.
28. Bugno M., Witek B., Bereta J., Bereta M., Edwards D.R., Kordula T. Reprogramming of TIMP-1 and TIMP-3 expression profiles in brain microvascular endothelial cells and astrocytes in response to proinflammatory cytokines. FEBS Lett. 448:1999;9-14.
29. Ito A., Mukaiyama A., Itoh Y., Nagase H., Thogersen I.B., Enghild J.J.et al. Degradation of interleukin 1beta by matrix metalloproteinases. J. Biol. Chem. 271:1996;14657-14660.
30. Hanemaaijer R., Koolwijk P., le Clercq L., de Vree W.J., van Hinsbergh V.W. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem. J. 296:1993;803-809.
31. Rosenberg G.A., Kornfeld M., Estrada E., Kelley R.O., Liotta L.A., Stetler-Stevenson W.G. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res. 576:1992;203-207.
32. Hayakawa T., Yamashita K., Ohuchi E., Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J. Cell Sci. 107:1994;2373-2379.
33. Valente P., Fassina G., Melchiori A., Masiello L., Cilli M., Vacca A.et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int. J. Cancer. 75:1998;246-253.
34. Maeda A., Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55:1996;300-309.